

**AMENDMENTS TO THE CLAIMS**

This listing of claims will replace all prior versions, and listings, of claims in the application.

**In the claims**

Claim 1-33 (Canceled)

Claim 34 (Currently amended): A composition comprising:  
an effective amount of a biologically active agent;  
a delivery-enhancing transporter having sufficient guanidino or amidino moieties to increase  
delivery of the biologically active agent across a biological barrier compared to the delivery of the  
biologically active agent in the absence of the transporter; and  
a pharmaceutically acceptable carrier;  
wherein said biologically active agent and said delivery-enhancing transporter form a non-  
covalently bound complex.~~The composition of claim 33, , and~~ wherein the biologically active agent  
is an antiviral agent selected from the group consisting of acyclovir, famciclovir, ganciclovir,  
foscarnet, idoxuridine, sorivudine, trifluridine, valacyclovir, cidofovir, didanosine, stavudine,  
zalcitabine, zidovudine, ribavirin and rimantadine.

Claim 35 (Currently amended): A composition comprising:  
an effective amount of a biologically active agent;  
a delivery-enhancing transporter having sufficient guanidino or amidino moieties to increase  
delivery of the biologically active agent across a biological barrier compared to the delivery of the  
biologically active agent in the absence of the transporter; and  
a pharmaceutically acceptable carrier;  
wherein said biologically active agent and said delivery-enhancing transporter form a non-  
covalently bound complex.~~The composition of claim 32, , and~~ wherein the biologically active agent  
is an antibacterial agent selected from the group consisting of nafcillin, oxacillin, penicillin,

amoxicillin, ampicillin, cefotaxime, ceftriaxone, rifampin, minocycline, ciprofloxacin, norfloxacin, erythromycin and vancomycin.

Claim 36 (Currently amended): A composition comprising:  
an effective amount of a biologically active agent;  
a delivery-enhancing transporter having sufficient guanidino or amidino moieties to increase delivery of the biologically active agent across a biological barrier compared to the delivery of the biologically active agent in the absence of the transporter; and  
a pharmaceutically acceptable carrier;  
wherein said biologically active agent and said delivery-enhancing transporter form a non-covalently bound complex.~~The composition of claim 32, , and~~ wherein the biologically active agent is an antifungal agent selected from the group consisting of amphotericin, itraconazole, ketoconazole, miconazole, nystatin, clotrimazole, fluconazole, ciclopirox, econazole, naftifine, terbinafine and griseofulvin.

Claim 37 (Currently amended): A composition comprising:  
an effective amount of a biologically active agent;  
a delivery-enhancing transporter having sufficient guanidino or amidino moieties to increase delivery of the biologically active agent across a biological barrier compared to the delivery of the biologically active agent in the absence of the transporter; and  
a pharmaceutically acceptable carrier;  
wherein said biologically active agent and said delivery-enhancing transporter form a non-covalently bound complex.~~The composition of claim 32, , and~~ wherein the biologically active agent is an antineoplastic agent selected from the group consisting of pentostatin, 6-mercaptopurine, 6-thioguanine, methotrexate, bleomycins, etoposide, teniposide, dactinomycin, daunorubicin, doxorubicin, mitoxantrone, hydroxyurea, 5-fluorouracil, cytarabine, fludarabine, mitomycin, cisplatin, procarbazine, dacarbazine, paclitaxel, colchicine, and the vinca alkaloids.

Claim 38 (Currently amended):                    A composition comprising:  
an effective amount of a biologically active agent;  
a delivery-enhancing transporter having sufficient guanidino or amidino moieties to increase  
delivery of the biologically active agent across a biological barrier compared to the delivery of the  
biologically active agent in the absence of the transporter; and  
a pharmaceutically acceptable carrier;  
wherein said biologically active agent and said delivery-enhancing transporter form a non-  
covalently bound complex.~~The composition of claim 32, , and~~ wherein the biologically active agent  
is an immunosuppressive agent selected from the group consisting of methotrexate, azathioprine,  
fluorouracil, hydroxyurea, b-thioguanine, chclophosphamide, mechloroethamine hydrochloride,  
carmustine, cyclosporine, taxol or a phosphate-cleavable taxol conjugate, tacrolimus, vinblastine,  
dapsone and sulfasalazine.

Claim 39 (Currently amended):                    A composition comprising:  
an effective amount of a biologically active agent;  
a delivery-enhancing transporter having sufficient guanidino or amidino moieties to increase  
delivery of the biologically active agent across a biological barrier compared to the delivery of the  
biologically active agent in the absence of the transporter; and  
a pharmaceutically acceptable carrier;  
wherein said biologically active agent and said delivery-enhancing transporter form a non-  
covalently bound complex.~~The composition of claim 32, , and~~ wherein the biologically active agent  
is an analgesic agent selected from the group consisting of lidocaine, bupivacaine, novocaine,  
procaine, tetracaine, benzocaine, cocaine, mepivacaine, etidocaine, proparacaine ropivacaine and  
prilocaine.

Claim 40 (Canceled)